psychiatrist.com logo

Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: What Does the Literature Tell Us?

John W. Newcomer, MD; Peter J. Weiden, MD; and Robert W. Buchanan, MD
Listen to Audio Introduction

Weight gain and metabolic abnormalities associated with the use of antipsychotic medications can increase risk for cardiovascular disease, diabetes mellitus, and obesity-related cancers.1-5 Other problems associated with antipsychotics, such as extrapyramidal symptoms (EPS) and prolactin elevation, can interfere with quality of life and/or ability to function.1 These problems present a dilemma for physicians who commonly face clinical decisions regarding whether or not to switch a patient from one antipsychotic to another to achieve a potential reduction in these effects.

Objective

With the notable exception of clozapine for treatment-resistant patients, there does not appear to be convincing evidence for differential efficacy among available first-line antipsychotics for the treatment of core positive symptoms.1-6 Therefore, in selecting among first-line antipyschotics (i.e., antipsychotics other than clozapine), clinicians commonly consider the relative impact of the overall adverse event profile of each medication in relation to the preferences and vulnerabilities of individual patients. The objective of this project was to provide evidence-based guidance concerning when and how it may be appropriate to undertake elective changes in antipsychotic medications with the goal of reducing risk of adverse effects, particularly adverse effects associated with increased long-term health risks.

2009 Schizophrenia PORT Recommendations

This project builds on the results of the National Institute of Mental Health (NIMH)–funded 2009 Schizophrenia Patient Outcomes Research Team (PORT) pharmacologic treatment recommendations.1 PORT concluded that the available evidence (eg, number of appropriately designed studies) was insufficient to make a recommendation concerning switching antipsychotics because of persistent problems with weight gain; EPS, including tardive dyskinesia; or prolactin elevation. PORT acknowledged that switching antipsychotics can lead to a reduction in a number of adverse effects, including weight gain and elevated prolactin levels.7 However, they concluded that, to develop a treatment recommendation in this area, evidence was required that the majority of individuals would experience significant improvement in these areas (eg, weight gain, lipid abnormalities) without clinical deterioration.1,7 PORT indicated that they expected the results of the Comparison of Antipsychotics for Metabolic Problems (CAMP) study8 (ongoing at that time) and other future studies to help clarify this issue.

Literature Review Methodology

To address this question raised by PORT, the literature on switching antipsychotics was reviewed, with a focus on studies published since the 2009 PORT treatment recommendations. PubMed was searched using the terms antipsychotics, switching, randomized, and clinical trials. Of the 121 articles identified, 76 were excluded because they were review articles, dealt with changes of antipsychotics for acute symptoms (eg, agitation), or involved disorders other than schizophrenia (eg, bipolar disorder, dementia). Reference lists in identified articles and unpublished posters were also consulted. Switching studies were limited to those dealing with oral antipsychotics; consideration of long-acting injectable agents was beyond the scope of this project. A final list of 45 studies was assembled.

Criteria for study selection. Case reports, case series, chart reviews, and open, observational studies provide uncontrolled evidence and are therefore generally useful only for "hypothesis generation." In contrast, controlled experimental studies, including gold-standard prospective randomized controlled trials (RCTs), are designed to address specific questions for the purpose of "hypothesis testing." The majority of recent switching studies have focused on weight and metabolic outcomes, since these results have the greatest potential for significant clinical and public health impact.

AV 1. Results of Literature Review (01:44)

AV1

The rest of this report briefly summarizes key findings from the literature in this area. For complete results on the literature review, please refer to the full publication of the results.9

Randomized Controlled Trials (Category 1)

Double-blind studies. In 2008, Newcomer et al10 published the results of the first double-blind RCT that examined switching to address undesirable body weight and lipid profiles. This was the only RCT on this question available to PORT.

AV 2. Weight and Metabolic Outcomes in Newcomer et al 2008 Study (01:50)

AV2

Significantly more participants who switched to aripiprazole (11.1%) than stayed on olanzapine (2.6%) had clinically relevant (≥ 7%) weight loss. Although there was a statistically significant advantage in endpoint scores for stayers versus switchers (3.09 vs 3.74, P < .001), and more switchers versus stayers discontinued treatment (36% vs 26%), the mean Clinical Global Improvement scale scores for both groups were in the range of “no change” to "minimal improvement."

The double-blind, randomized CAMP study, published by Stroup et al8 in 2011, evaluated change in non–high-density lipoprotein (non-HDL) cholesterol and the efficacy of switching to aripiprazole versus staying on the current agent. Participants with schizophrenia or schizoaffective disorder with a body mass index (BMI) ≥ 27 and a non-HDL cholesterol level ≥ 130 mg/dL who were receiving a stable dose of olanzapine, quetiapine, or risperidone were randomly assigned to switch to aripiprazole (n = 109) or stay on their current medication (n = 106) for 24 weeks.

AV 3. Outcomes After 24 Weeks in Stroup et al CAMP Study (01:08)

AV3

The small weight loss among stayers, in contrast to the persistent weight gain seen in the Newcomer et al10 study, may be related to the behavioral exercise and diet intervention all study participants received. As in Newcomer and colleagues’ study, beneficial changes in lipids occurred quickly (eg, over the first month), whereas weight changes were more gradual. As reported in other studies,10,11 a significantly higher percentage (44%) of switchers than stayers (25%) discontinued the medication before the end of the study. However, differences in serious adverse events and number of hospitalizations between the 2 groups were small.

The CAMP results8 make it possible to generalize from the Newcomer et al10 results, since the CAMP study found similar results for people switching from a variety of different agents.

Other randomized studies. Most of the other recent category 1 studies, while randomized and controlled, were not double-blind. Thus, while they provide useful supportive findings concerning reductions in parameters such as weight, EPS, and lipid and prolactin levels, it is not possible to rule out effects related to patient or investigator bias because of the open-label nature of the studies. In a randomized, open-label study, Kinon et al12 reported a reduction in prolactin levels and improvement in sexual functioning in participants switched from a first-generation antipsychotic (FGA) or risperidone to olanzapine (n = 27) compared with those who stayed on an FGA (n = 9) or risperidone (n = 18). Cortese et al13 found improvement in EPS (ie, parkinsonism, akathisia, and dyskinesia) in participants randomly assigned to switch from olanzapine, risperidone, or an FGA to quetiapine (n = 13) compared to those who continued on the previous antipsychotic (n = 9). Chen et al14 reported statistically significant improvements in weight, BMI, and triglyceride and HDL levels in participants randomly assigned to switch to aripiprazole (n = 24) or ziprasidone (n = 28) from other antipsychotics.

Summary. Evidence from category 1 studies, in particular the Newcomer et al10 and Stroup et al8 studies, indicates that switching to a low metabolic risk antipsychotic under controlled conditions can produce benefits in both weight/BMI and lipid profile without significant risk of clinical deterioration. Randomized controlled open-label studies also suggest benefits of switching medications because of EPS or elevated prolactin levels. One caveat in interpreting these results is that people treated with clozapine were excluded from these studies, so that the relative safety of switching from clozapine for metabolic reasons remains understudied but associated with higher risk for clinical worsening in the few studies concerning clozapine switching to date.15,16

Randomized Trials Not Specifically Designed as Switching Studies (Category 2)

The majority of studies in category 2 involved secondary analyses of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study,6 which enrolled approximately 1,500 people with schizophrenia (the 3 newest antipsychotics, asenapine, iloperidone, and lurasidone, were not included in CATIE or the PORT deliberations). CATIE is the largest practical clinical trial conducted to evaluate antipsychotic efficacy. The CATIE study did not support differences in efficacy among antipsychotics other than clozapine, but did find marked variability in adverse effect profiles. Several analyses of CATIE data have addressed relevant switching questions.

AV 4. Key Findings About Switching From Secondary Analyses of CATIE Data (02:15)

AV4

Several other category 2 studies addressed relevant questions. Based on a 1-year randomized open-label cost-effectiveness study, Faries et al20 reported poorer clinical and economic outcomes (ie, more frequent and rapid use of acute care services) among switchers (n = 191) than among stayers (n = 460) and improvements in clinical outcomes, but more weight gain, among those who switched from risperidone to olanzapine than among those treated with risperidone.21

Stahl et al22 reported results from a 6-month open-label extension of the Program to Evaluate the Antipsychotic Response to Lurasidone (PEARL 2) randomized, placebo-controlled, double-blind study, a large multicenter trial evaluating the efficacy of 40 and 120 mg/d of lurasidone versus placebo or olanzapine 15 mg/d. Participants who completed 6 weeks of double-blind treatment with lurasidone, olanzapine, or placebo were eligible to continue treatment with lurasidone for up to 6 months (44.5% [113/254] completed 6 months). In this continuation phase, participants previously treated with olanzapine experienced decreases in weight (mean reduction of 1.8 kg) and lipid levels while efficacy was maintained. Participants previously treated with placebo or lurasidone had minimal changes in these parameters.

Summary. Evidence from category 2 studies generally supports the observation from category 1 studies8,10 that switching from antipsychotics with higher metabolic risk to those with lower risk under controlled conditions can produce metabolic and weight benefits without significant risk of clinical deterioration. However, studies also confirmed that participants switched to a new antipsychotic are more likely to discontinue treatment than those who remain on the same agent, highlighting the need to optimize current treatment and perform a risk-benefit assessment before switching to a new agent.

Uncontrolled and/or Open-Label Trials (Category 3)

Switching methods. Of the 16 studies in category 3, the majority examined strategies for switching from one medication to another (ie, stopping the first agent before starting the new medication, maintaining a therapeutic dose of the first medication while titrating up to a therapeutic dose of the new medication, or gradually discontinuing the first medication while titrating the new medication to a therapeutic dose). In general, these studies found few differences in outcomes among the strategies, although there was some evidence favoring more gradual discontinuation of the first antipsychotic to minimize problems early in the switching process.23-27

As an example, 2 recent studies supported this finding. In a 6-week, multicenter, randomized, open-label study in which 240 stable participants were switched from other antipsychotics to lurasidone because of insufficient efficacy or safety/tolerability concerns, McEvoy et al27 used a gradual discontinuation strategy to taper participants off their initial antipsychotic and 3 different strategies to titrate lurasidone. The first medication was tapered by 50% by day 7 and discontinued by day 14, with participants randomly assigned to 1 of 3 methods of starting lurasidone: 40 mg/d for 2 weeks, 80 mg/d for 2 weeks, and 40 mg/d for week 1 and 80 mg/d for week 2. After 6 weeks, participants were successfully switched regardless of method of starting the new medication.

Data from another recent 12-week, randomized, multicenter, open-label switching study,26-28 in which participants were switched from olanzapine (n = 155), risperidone (n = 175), or aripiprazole (n = 170) to iloperidone, showed that more participants in the group who were switched abruptly rather than gradually discontinued due to adverse events. The difference in discontinuations was primarily due to dizziness associated with α1 antagonism during the first 1–2 weeks of iloperidone treatment, which decreased over time.

Switching due to adverse effects. Data from open-label uncontrolled studies concerning changes in weight, metabolic parameters, and other side effects after switching antipsychotics are generally consistent with findings from controlled trials.26-32 The following sections briefly review findings from more recent studies in this area.

Weight gain and/or metabolic abnormalities. In 3 long-term, open-label extension studies in which participants switched from risperidone (n = 43), olanzapine (n = 71), or an FGA (n = 71) to ziprasidone and could continue ziprasidone for up to 58 weeks,31 clinically significant and sustained reductions in weight, BMI, and total cholesterol and triglyceride levels were observed in those who switched from risperidone or olanzapine to ziprasidone.

In the McEvoy et al27 6-week study discussed earlier, subjects switched to lurasidone showed mean decreases in weight and improvements in metabolic parameters.

Prolactin elevation. Byerly et al32 found that elevated prolactin levels in participants treated with risperidone decreased significantly and returned to normal 1 week after switching to aripiprazole, with this change maintained for the 8 weeks of the study.

Sedation. The McEvoy et al27 switching study provided useful information on switching from more to less sedating agents.

AV 5. Time to Treatment Failure When Switching From Sedating vs Non-Sedating Antipsychotics (01:38)

AV5

Summary. Data from the open-label, uncontrolled category 3 studies generally confirm and extend findings from the category 1 and 2 studies. A majority of category 3 studies examined switching methods, with a number supporting more gradual discontinuation of the first agent to minimize problems early in the switching process, particularly when starting an agent that requires gradual titration (eg, iloperidone, due to hypotension related to α1 antagonism). Studies in all 3 categories suggest that the magnitude of change in parameters such as weight, lipids, prolactin, and EPS can vary substantially depending on the specific agents involved in the switch. Thus, the greatest reduction in weight would be expected when switching from olanzapine to an agent with low liability for weight gain, the greatest reduction in EPS or prolactin would be expected when switching from an FGA or risperidone, and the greatest changes in sedation would be expected when switching from a more sedating (olanzapine or quetiapine) to a less sedating agent.

Part 2 of this online series will present clinical recommendations based on the evidence reviewed here.

References
  1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 Schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. doi:10.1093/schbul/sbp116 PubMed
  2. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298(15):1794–1796. doi:10.1001/jama.298.15.1794 PubMed
  3. Correll CU, Druss BG, Lombardo I, et al. Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv. 2010;61(9):892–898. doi:10.1176/appi.ps.61.9.892 PubMed
  4. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126. doi:10.1038/nrendo.2011.156 PubMed
  5. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm):A42. Accessed August 18, 2011. PubMed
  6. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. doi:10.1056/NEJMoa051688 PubMed
  7. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. PORT supplementary material: psychopharmacological summary statements and evidence summaries, 2010. Schizophr Bull. http://schizophreniabulletin.oxfordjournals.org/content/36/1/71/suppl/DC1. Accessed September 26, 2013.
  8. Stroup TS, McEvoy JP, Ring KD, et al. Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry. 2011;168(9):947–956. doi:10.1176/appi.ajp.2011.10111609 PubMed
  9. Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry. 2013;74(11):1108–1120. doi:10.4088/JCP.12028ah1 PubMed
  10. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046–1056. doi:10.4088/JCP.v69n0702 PubMed
  11. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090–2095. doi:10.1176/appi.ajp.163.12.2090 PubMed
  12. Kinon BJ, Ahl J, Liu-Seifert H, et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31(5):577–588. doi:10.1016/j.psyneuen.2005.12.006 PubMed
  13. Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(1):69–73. doi:10.1097/jcp.0b013e318160864f PubMed
  14. Chen Y, Bobo WV, Watts K, et al. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol. 2012;26(9):1201–1210. doi:10.1177/0269881111430748 PubMed
  15. Lin CC, Chiu HJ, Chen JY, et al. Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. J Clin Psychopharmacol. 2013;33(2):211–214. doi:10.1097/JCP.0b013e31828700c7 PubMed
  16. Tollefson GD, Dellva MA, Mattler CA, et al, and The Collaborative Crossover Study Group. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. J Clin Psychopharmacol. 1999;19(5):435–443. doi:10.1097/00004714-199910000-00007 PubMed
  17. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008;105(1-3):175–187. doi:10.1016/j.schres.2008.07.006 PubMed
  18. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009;107(1):22–29. doi:10.1016/j.schres.2008.09.031 PubMed
  19. Hermes E, Nasrallah H, Davis V, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011;128(1-3):166–170. doi:10.1016/j.schres.2011.01.022 PubMed
  20. Faries DE, Ascher-Svanum H, Nyhuis AW, et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9(1):54. doi:10.1186/1471-244X-9-54 PubMed
  21. Faries DE, Ascher-Svanum H, Nyhuis AW, et al. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin. 2008;24(5):1399–1405. doi:10.1185/030079908X297385 PubMed
  22. Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507–515. doi:10.4088/JCP.12m08084 PubMed
  23. Ganguli R, Brar JS, Mahmoud R, et al. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med. 2008;6(1):17. doi:10.1186/1741-7015-6-17 PubMed
  24. Pae CU, Serretti A, Chiesa A, et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol. 2009;19(8):562–570. doi:10.1016/j.euroneuro.2009.04.002 PubMed
  25. Stip E, Zhornitsky S, Potvin S, et al. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):997–1000. doi:10.1016/j.pnpbp.2010.05.010 PubMed
  26. Weiden PJ. Alva G, Brams M, et al. Efficacy and safety/tolerability of two approaches for switching to iloperidone in patients with schizophrenia. Poster presented at the New Clinical Drug Evaluation Unit Annual Meeting, Phoenix, AZ, May 29–June 1, 2012.
  27. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170–179. doi:10.4088/JCP.12m07992 PubMed
  28. Citrome L, Kianifard F, Meng X, et al. Discontinuations following a switch from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia: the i-FANS study. Poster presented at American College of Neuropsychopharmacology Annual Meeting, Hollywood, FL, December 2–6, 2012.
  29. Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580–588. doi:10.4088/JCP.v64n0514 PubMed
  30. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595–600. doi:10.1097/01.jcp.0000095347.32154.08 PubMed
  31. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985–994. doi:10.1038/sj.npp.1301482 PubMed
  32. Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107(2–3):218–222. doi:10.1016/j.schres.2008.09.019 PubMed
John W. Newcomer, MD

John W. Newcomer, MD

Executive Vice Dean, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida

Peter J. Weiden, MD 

Peter J. Weiden, MD

Professor of Psychiatry, University of Illinois at Chicago

Robert W. Buchanan, MD 

Robert W. Buchanan, MD

Professor of Psychiatry, University of Maryland School of Medicine Interim Director, Maryland Psychiatric Research Center, Baltimore, Maryland

Supported by an educational grant from Sunovion Pharmaceuticals, Inc.

 

doi:10.4088/JCP.12028br3

Psychiatrist.com The Journal of Clinical Psychiatry The Primary Care Companion for CNS Disorders The CME Institute Neurology Knowledge Terms of Use Privacy Policy